Medical/Pharmaceuticals

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced thatDavid Stamler, M.D., ...

2023-01-03 23:25 1639

Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test

IRVINE, Calif., Jan. 3, 2023 /PRNewswire/ -- Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been granted Breakthro...

2023-01-03 22:24 1015

ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Receives FDA "Study May Proceed" Letter for PRO1160, a CD70-Directed ADC

* PRO1184 first-in human study initiated and first patients dosed * PRO1160 first-in-human study cleared for initiation in the US * Both PRO1184 and PRO1160 are based on a novel, proprietary, and internally developed linker-drug technology platform SUZHOU, China and WOODINVILLE, Wash., Jan. ...

2023-01-03 20:00 2504

Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference

SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...

2023-01-03 14:10 1916

Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office

- Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkinson's and Alzheimer's - MELBOURNE, Australia and SAN FRANCISCO, Dec. 29, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company d...

2022-12-29 23:25 2649

Qilu Pharmaceutical Announces Progress of Clinical Study of QL1706, an Innovative Bifunctional Antibody

JINAN, China, Dec. 29, 2022 /PRNewswire/ -- In 2022, Qilu Pharmaceutical revealed the latest progress being made with several clinical studies involving its innovativebifunctional antibody, QL1706, at several international and Chinese academic conferences, including the American Association for C...

2022-12-29 14:32 1885

A Korean DTx Company LifeSemantics to Unveil the Redpill Breath Solution for Pulmonary Rehabilitation DTx at CES 2023

* LifeSemantics will participate in the Digital Healthcare section of CES 2023 and unveil theRedpill Breath Solution, a pulmonary rehabilitation DTx. * The company will open a booth at the Korean pavilion in Eureka Park and offer an opportunity to experience the solution. * LifeSemantics wil...

2022-12-28 22:00 2254

China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask

HAIKOU, China, Dec. 28, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the launch of N95 medical protect...

2022-12-28 21:00 2602

EOFlow Submits Application to the U.S. FDA for its Wearable Insulin Pump 'EOPatch'

* Plans to finalize its U.S. distribution strategy in 2023 * Aims to enter the U.S., the world's largest diabetes market, with its current disposable wearable insulin pump 'EOPatch' SAN JOSE, Calif. , Dec. 27, 2022 /PRNewswire/ -- EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a p...

2022-12-27 15:48 1893

GeneQuantum and WuXi XDC Entered into Strategic Collaboration to Empower Innovative Bioconjugate Development

SUZHOU, China, Dec. 26, 2022 /PRNewswire/ -- GeneQuantum Healthcare (GQ), a global innovative biotechnology company dedicated to the development of the next generation bioconjugate drugs , and WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), ann...

2022-12-26 23:01 2721

CJ CheilJedang, and Emmyon, Inc. sign a Licensing Agreement to commercialize a dietary supplement with natural extracts for use in significant improvement of skeletal muscle mass and function in humans.

SEOUL, South Korea and ROCHESTER, Minn., Dec. 26, 2022 /PRNewswire/ -- CJ Food and Nutrition Tech (CJ FNT), a newly formed business unit of CJ CheilJedang, a South Korea based global food and nutrition company, and Emmyon, Inc., a privately-held biotechnology start-up company based inRochester, MN...

2022-12-26 21:00 3014

Hyphens Pharma licenses Winlevi® for all 10 ASEAN countries from Cosmo Pharmaceuticals

* Winlevi® is a first-in-class topical drug for the treatment of acne approved by U.S. FDA inAugust 2020. * It will reinforce our Proprietary Brand segment's dermatological franchise. SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Hyphens Pharma International Limited (" Hyphens Pharma", or the "Comp...

2022-12-23 17:00 2086

PVmed Raises US $14 Million Series A Funding from Cherami, Philips, JHF, COCOCAPITAL, and Strategy Capital

Will Support Rapid Expansion of PVmed's AI Cancer Treatment Product Portfolio GUANGZHOU, China, Dec. 22, 2022 /PRNewswire/ -- Perception Vision Medical Technologies Co., Ltd. (PVmed), a global artificial intelligence (AI) cancer treatment company, headquartered inGuangzhou, China, has secured US ...

2022-12-23 11:31 2362

Ubitus and Smart Surgery enable doctors to practice robotic surgery with VR streaming

TOKYO, Dec. 22, 2022 /PRNewswire/ -- Ubitus K.K. (hereinafter Ubitus), a world-leading metaverse solution provider, supports Smart Surgery Technology to roll out its VR driven surgery simulation application – Sim Surgery. Smart Surgery Technology successfully demonstrated this innovative product ...

2022-12-22 22:00 2726

FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial

Exploring Xanamem® and the "cortisol hypothesis" for more than 6 million Americans suffering from Alzheimer's Disease[1]  SYDNEY, Dec. 22, 2022 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) is pleased to announce receipt today of agreement from the US Food and Drug Administration (FDA) to...

2022-12-22 20:30 1984

IASO Bio Announces U.S. FDA Approval of Clinical Trial Application for BCMA CAR-T CT103A for Relapsed/Refractory Multiple Myeloma

SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 22, 2022 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products,, today announced that the Investiga...

2022-12-22 16:38 2089

Nuevocor to Present at Biotech Showcase during JPM week and at Keystone Symposium on Heart Development and Disease

SINGAPORE, Dec. 21, 2022 /PRNewswire/ -- Nuevocor , a pre-clinical stage cardiac gene therapy company, announced today that it will be presenting at the Biotech Showcase during JPM week, taking place inSan Francisco, CA, USA from January 9 to 11, 2023. Nuevocor will als...

2022-12-21 22:00 2327

I Peace, Inc. honored in BioSpectrum Asia Excellence Award 2022 with "Special Recognition in Cell Therapy"

PALO ALTO, Calif., Dec. 21, 2022 /PRNewswire/ -- I Peace, Inc. ( https://www.ipeace.com ), has been awarded a "Special Recognition in Cell Therapy" during BioSpectrum Asia Excellence Award 2022 ceremony held inSingapore on December 2 ( https://www.biospectrumasia.com/news/...

2022-12-21 15:10 2106

QureBio Ltd. to Present its Q-1802 Clinical Phase Ⅰ Data at 2023 ASCO-GI Meetings

SHANGHAI, Dec. 20, 2022 /PRNewswire/ --  QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineeredBiopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today announced that Phase Ⅰ Clinical D...

2022-12-21 10:30 2349

WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index

SHANGHAI, Dec. 20, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, today announced that it has been included in the 2022 Dow Jones Sustainability™ World Index (DJSI). This demonstrates th...

2022-12-21 08:00 2406
1 ... 979899100101102103 ... 215

Week's Top Stories